Fvii Gene Polymorphism And Coagulation Activity Role In Arterial Thrombotic Diseases

BACKGROUND: Cardiovascular diseases have long been the major causes resulting in mortalities and disabilities around the world. Through half century's studies, it has been realized that this kind of diseases may be caused by multiple factors; The imbalance of coagulation and fibrinolysis is an important cause participating in the pathogenesis of cardiovascular diseases; Diabetes mellitus is intimately associated with cardiovascular mortality and morbidity and is also the risk factor of cardialvascular disease.In 1980 and 1985, Meade and his colleagues confirmed in their two reports of the Northwick Park Heart Study(NPHS) that high plasma FVIIc(FVII coagulant activity) is a predictor related to the pathogenesis and the prognosis of IHD. In 1991, Green reported FVII gene polymorphisms of the restricton enzyme Msp I acting site could influence plasma FVII coagulant activity. Carriers of the M2 allele(encoding Gln₃₅₃) have levels of FVIIc lower than those of Ml allele(encoding Arg₃₅₃) and have reduced acute tlirombotic events. FVII M2 allele is a protective factor of the arterial tlirombotic diseases.But the occurrence of FVII M2 allele is rare in general population (lower than 10%) in studies abroad. There is no report about the correlation between FVII M2 allele and FVIIa(activated FVII) so far. The influence on FVII protein(FVIIAg) by FVII polymorphism was reported in very few samples in only one paper. The viewpoint that the M2 allele is a protective factor in thrombostic diseases seems inappropriate.OBJECTIVES: This study is to investigate: 1. The occurrence of FVII M2 allele in Chinese population; 2. The relationship between FVII polymorphism and FVII coagulant activity and FVIIAg; 3. The roles of...